Search results for CSF

Gimsilumab Biosimilar – Anti-CSF2 , GM-CSF mAb – Research Grade, ProteoGenix, PX-TA1478

Description of Gimsilumab Biosimilar - Anti-CSF2 , GM-CSF mAb - Research Grade Introduction Gimsilumab biosimilar, also known as anti-CSF2, is a monoclonal antibody (mAb) that targets the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). This protein plays a crucial role in the immune system by promoting the production and differentiation of white blood cells. Gimsilumab biosimilar is a research-grade version of the original drug, and its structure, activity, and potential applications will be discussed in this article. Structure of Gimsilumab Biosimilar Gimsilumab biosimilar is a fully humanized IgG1 monoclonal antibody, meaning that it is made up of human immunoglobulin G1 molecules. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 50 kDa. The antibody has a Y-shaped structure, with two antigen-binding sites located at the tips of the Y. These binding sites are specific for GM-CSF, allowing Gimsilumab biosimilar to bind to and neutralize the cytokine. Activity of Gimsilumab Biosimilar Gimsilumab biosimilar works by blocking the activity of GM-CSF, which is known to be involved in the pathogenesis of various inflammatory and autoimmune diseases. By binding to GM-CSF, Gimsilumab biosimilar prevents the cytokine from binding to its receptor on immune cells, thereby inhibiting its signaling pathway. This leads to a decrease in the production and activation of inflammatory cells, ultimately reducing inflammation and tissue damage. Studies have shown that Gimsilumab biosimilar has a high affinity for GM-CSF, with a dissociation constant (Kd) of 0.7 nM. This indicates that the antibody has a strong binding ability, making it an effective inhibitor of GM-CSF activity. Additionally, Gimsilumab biosimilar has been found to have a long half-life of approximately 21 days, allowing for sustained inhibition of GM-CSF and prolonged therapeutic effects. Application of Gimsilumab Biosimilar Gimsilumab biosimilar is currently being investigated for its potential use in the treatment of various inflammatory and autoimmune diseases. These include rheumatoid arthritis, psoriasis, and multiple sclerosis, all of which are characterized by excessive inflammation and immune cell activation. By targeting GM-CSF, Gimsilumab biosimilar has the potential to provide a more targeted and effective treatment option for these conditions. In addition, Gimsilumab biosimilar has also shown promise in the treatment of COVID-19. Studies have shown that GM-CSF plays a crucial role in the development of cytokine storm, a severe immune response that can lead to respiratory failure and death in COVID-19 patients. By inhibiting GM-CSF, Gimsilumab biosimilar may be able to reduce the severity of cytokine storm and improve outcomes in patients with severe COVID-19. Conclusion Gimsilumab biosimilar, also known as anti-CSF2, is a monoclonal antibody that targets the cytokine GM-CSF. Its structure, activity, and potential applications make it a promising therapeutic option for inflammatory and autoimmune diseases, as well as for COVID-19. Further research and clinical trials are needed to fully evaluate the efficacy and safety of this biosimilar, but early results are promising and suggest that it may provide a more targeted and effective treatment option for a range of conditions.

Namilumab Biosimilar – Anti-CSF2, GM-CSF mAb – Research Grade, ProteoGenix, PX-TA1259

Description of Namilumab Biosimilar - Anti-CSF2, GM-CSF mAb - Research Grade General information on Anti-CSF2/GM-CSF[Homo sapiens] (Namilumab) Monoclonal Antibody Namilumab has beeninvestigated for the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

Biotin Anti-CSF-1-R antibody [12-3A3-1B10], Abcam, AB95730

Otilimab Biosimilar – Anti-CSF2, GM-CSF mAb – Research Grade, ProteoGenix, PX-TA1141

Description of Otilimab Biosimilar - Anti-CSF2, GM-CSF mAb - Research Grade Introduction Otilimab Biosimilar, also known as Anti-CSF2, GM-CSF mAb, is a research grade monoclonal antibody that has shown promising results in the treatment of various inflammatory and autoimmune diseases. In this article, we will delve into the structure, activity, and potential applications of this novel therapeutic agent. Structure of Otilimab Biosimilar Otilimab Biosimilar is a recombinant, humanized monoclonal antibody that specifically targets the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody is produced using Chinese hamster ovary (CHO) cells and is glycosylated, meaning it has sugar molecules attached to it. This glycosylation is important for the stability and activity of the antibody. Activity of Otilimab Biosimilar As mentioned earlier, Otilimab Biosimilar targets GM-CSF, a cytokine that plays a crucial role in the development and activation of immune cells. By binding to GM-CSF, Otilimab Biosimilar blocks its activity, leading to a reduction in the production and activation of inflammatory cells such as neutrophils, macrophages, and dendritic cells. This results in a decrease in the levels of pro-inflammatory cytokines and chemokines, ultimately leading to a decrease in inflammation. Applications of Otilimab Biosimilar Otilimab Biosimilar has shown promising results in various pre-clinical and clinical studies as a potential treatment for inflammatory and autoimmune diseases. Some of the conditions it has been studied for include rheumatoid arthritis, psoriasis, multiple sclerosis, and asthma. Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and destruction of joints. Otilimab Biosimilar has been shown to significantly reduce disease activity in patients with moderate to severe RA, as well as improve physical function and reduce joint damage. It has also been well-tolerated in clinical trials, with a favorable safety profile. Psoriasis Psoriasis is a chronic skin disease caused by an overactive immune system. In a phase II clinical trial, Otilimab Biosimilar was found to be effective in reducing the severity of psoriasis, with a significant improvement in skin lesions and symptoms. It was also well-tolerated, with no serious adverse events reported. Multiple Sclerosis Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system. Otilimab Biosimilar has shown promising results in reducing the number of relapses and slowing disease progression in patients with relapsing-remitting MS. It has also been shown to improve brain lesions and physical functioning in these patients. Asthma Asthma is a chronic respiratory disease characterized by airway inflammation and narrowing. Otilimab Biosimilar has been studied as a potential treatment for severe asthma, with promising results. It has been shown to reduce asthma exacerbations and improve lung function in patients with uncontrolled asthma. Conclusion In conclusion, Otilimab Biosimilar, also known as Anti-CSF2, GM-CSF mAb, is a research grade monoclonal antibody with a unique structure and mechanism of action. It has shown promising results in various inflammatory and autoimmune diseases, making it a potential therapeutic option for these conditions. Further research and clinical trials are needed to fully understand the efficacy and safety of this novel antibody, but it holds great potential in improving the lives of patients with these debilitating diseases.

PE Anti-CSF-1-R antibody [12-3A3-1B10], Abcam, AB95731

Excitation: 488 nm Emission: 575 nm.

Alexa Fluor® 488 Anti-M-CSF antibody [EP1179Y], Abcam, AB206052

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or [email protected].

Anti-GM-CSF antibody [EPR23689-17] - BSA and Azide free, Abcam, AB277945

ab277945 is the carrier-free version of ab227031 . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.

Anti-GM-CSF antibody [EPR25991-223] (BSA and Azide free), Abcam, AB300496

ab300496 is the carrier-free version of ab300495 . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.

Anti-GM-CSF antibody [EPR28743-78] - BSA and Azide free, Abcam, AB316863

ab316863 is the carrier-free version of ab316862 . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.

GM-CSF Receptor alpha (E8Z3S) Rabbit Monoclonal Antibody#69817, Cell Signaling Technology (CST), 69817

GM-CSF Receptor alpha (E8Z3S) Rabbit Monoclonal Antibody recognizes endogenous levels of total GM-CSF Receptor α protein. This antibody does not cross-react with GM-CSF Receptor β protein. Based on the antigen sequence, this antibody is predicted to recognize multiple isoforms of GM-CSF Receptor α protein, including secreted isoforms.